Quantum Biopharma Ltd. (QNTM)
Quantum BioPharma develops drug candidates for neurodegenerative, inflammatory, metabolic and alcohol misuse disorders. It last closed at $1.29 on Nov 20, down 9.15% on the day.
Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on QNTM
Technical AnalysisPrices may be delayed
The stock is 53% below its 20 day and 110% below its 50 day average. It is 180% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $1.26, and the nearest resistance the Pivot at $1.32.
| RSI (14) | 22.21 | Oversold below 30 | Oversold |
| MACD | -0.35 | Below its signal line | Bearish |
| Stochastic | 9.2 | Near the bottom of its range | Oversold |
| ADX (14) | 41.9 | Strong downtrend | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -145.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −38.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.21 | Typical daily range, 16.0% of price |
| RSI (14) | 33.69 | Weak, oversold below 30 | Neutral |
| MACD | -0.84 | Below its signal line | Bearish |
| Stochastic | 1.5 | Near the bottom of its range | Oversold |
| ADX (14) | 13.3 | No clear trend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -200.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −59.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.88 | Typical daily range, 67.9% of price |
What happened before
See how QNTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How QNTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options FlowPrices may be delayed
90DNo whale options trades in QNTM in the last 90 days.
QNTM Institutional Ownership
Full report →- ▲14 buying vs 5 selling
- ▲Shares held by funds +28.9%
- ▲Funds holding +2
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 29 | 27 | +7.4% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 5 / 9 | 3 / 8 | +27.3% |
| Reduced / sold out | 1 / 4 | 4 / 3 | −28.6% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNTM is in one of them and how their past QNTM trades turned out.
QNTM News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered QNTM in an article yet. Here's the latest on the wider market.
- Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up
- Quantum Biopharma Ltd.: Foreign issuer report
- Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares
- Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold
About Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company based in Toronto that develops drug candidates for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Its lead candidate, Lucid-MS, is being researched as a possible treatment for multiple sclerosis and is at the preclinical stage. The company has also licensed unbuzzd, a dietary supplement drink intended for people who have consumed excess alcohol, to Unbuzzd and Celly U.S. for retail sale. It is also developing a healthcare product for use in hospitals and emergency departments.
- Headquarters
- Toronto
